Could a Saliva Test Replace the Glucose Drink in Pregnancy? The Science Isn’t There Yet

Could a simple saliva sample someday replace the glucose drink used to screen for gestational diabetes? Researchers are exploring that possibility, but the evidence remains preliminary. A recent scoping review examining salivary biomarkers for gestational diabetes suggests that saliva may contain useful signals of elevated blood sugar during pregnancy. However, these findings do not establish saliva testing as a reliable alternative to standard screening. A review published in BMC Endocrine Disorders provides a closer look at the promise and limitations of this emerging approach.

Table of Contents

1. Why Saliva Testing Could Change Gestational Diabetes Screening
2. What Research Reveals About Salivary Biomarkers for Gestational Diabetes
3. Why Saliva Testing Is Not Ready to Replace Blood Tests
4. What the Findings Mean for Prenatal Diabetes Care
5. Conclusion
6. Frequently Asked Questions

Why Saliva Testing Could Change Gestational Diabetes Screening

Gestational diabetes mellitus (GDM) develops when blood glucose levels become elevated during pregnancy. Although the condition often causes no noticeable symptoms, untreated hyperglycemia can increase the risk of complications for both mother and baby. These include excessive fetal growth, birth complications, and maternal high blood pressure.

Currently, the American Diabetes Association recommends gestational diabetes screening at 24 to 28 weeks for most pregnant individuals who have not already been diagnosed with diabetes or significant abnormal glucose metabolism.

The established approaches include a one-step oral glucose tolerance test (OGTT) or a two-step strategy beginning with a glucose challenge test. Both require blood collection, and some patients experience nausea or discomfort from the glucose drink.

Consequently, researchers are investigating whether saliva could provide a simpler way to identify abnormal glucose metabolism.

Unlike blood testing, saliva collection does not require needles. Furthermore, samples may be easier to collect repeatedly, particularly in settings where laboratory access is limited.

A reliable saliva-based screening method could potentially improve patient comfort and expand access to prenatal testing. However, convenience alone cannot justify replacing methods with established diagnostic accuracy.

What Research Reveals About Salivary Biomarkers for Gestational Diabetes

A scoping review published in BMC Endocrine Disorders evaluated 31 reports from nine countries.

Researchers examined studies comparing salivary biomarkers in pregnant individuals with hyperglycemia and those with normal glucose levels. Most studies focused specifically on gestational diabetes.

The findings identified several biological signals that deserve further investigation. Although some markers showed encouraging results, the evidence varied considerably between studies.

Salivary Glucose and Oxidative Stress Markers

Salivary glucose emerged as one potential indicator of altered blood sugar regulation. Both studies examining this marker found higher glucose concentrations after meals or glucose loading among participants with gestational diabetes.

Importantly, one study reported an area under the receiver operating characteristic curve (AUC) of 0.865 for saliva collected two hours after a meal.

An AUC measures how well a test distinguishes between individuals with and without a condition. Although this result appears encouraging, it came from a single study and does not establish clinical reliability.

Researchers also examined malondialdehyde (MDA), a marker associated with oxidative stress.

One study reported an AUC of 0.812 for MDA. Nevertheless, findings across studies were inconsistent, making its usefulness uncertain.

Hormones, Inflammation, and Oral Bacteria

Other research explored adipokines, which are proteins involved in metabolism and inflammation.

Two candidates, visfatin and resistin, produced reported AUC values of 0.705 and 0.641, respectively. These results suggest possible biological associations, but their ability to support accurate screening remains limited.

Additionally, researchers investigated inflammatory markers and differences in the oral microbiome.

Some studies identified distinct patterns of oral bacteria among participants with gestational diabetes. However, oral health, gum inflammation, and other factors can influence these findings.

Together, these findings suggest that combining multiple salivary biomarkers could improve future screening methods for gestational diabetes. However, this approach still requires testing in larger, independent populations before its usefulness can be established.

Why Saliva Testing Is Not Ready to Replace Blood Tests

Despite the promising findings, several important limitations prevent saliva-based testing from entering routine prenatal care.

First, many included studies used cross-sectional or case-control designs. These approaches can identify associations but cannot establish how accurately a test would perform during routine screening.

Second, saliva collection methods varied between studies. Differences in meal timing, sample processing, laboratory techniques, and saliva flow may influence biomarker concentrations.

Third, some study populations potentially overlapped, limiting the amount of independent evidence available.

Furthermore, oral inflammation and periodontal disease can alter biological signals in saliva. Without accounting for these factors, researchers may mistake changes related to oral health for markers of gestational diabetes.

Most importantly, reported diagnostic models lacked external validation in independent populations.

A biomarker that performs well in one study may not achieve similar results across different clinics, populations, or stages of pregnancy.

Therefore, the review's authors emphasized the need for larger prospective studies, standardized procedures, and independent validation.

Until those requirements are met, saliva testing cannot reliably replace established blood-based screening.

What the Findings Mean for Prenatal Diabetes Care

For healthcare professionals, the findings highlight an emerging research opportunity rather than an immediate change in clinical practice.

The American Diabetes Association's 2026 Standards of Care continue to support established plasma glucose-based approaches for detecting gestational diabetes.

Clinicians should therefore continue following recommended screening protocols while monitoring developments in noninvasive diagnostics.

Still, research into saliva-based biomarkers could eventually lead to better risk assessment and more accessible gestational diabetes screening.

For example, researchers might investigate whether combining salivary glucose, oxidative stress markers, and microbial patterns improves accuracy.

Future studies must also establish appropriate thresholds, testing times, and performance across diverse patient populations.

Equally important, investigators need to determine whether saliva-based screening improves clinical outcomes without increasing missed diagnoses.

Healthcare professionals can explore additional research and clinical developments through Diabetes in Control, which covers diabetes screening, treatment, and emerging diagnostic technologies.

For now, clinicians should explain that experimental saliva tests are not substitutes for recommended prenatal screening. Patients with questions about gestational diabetes testing should consult their obstetric or diabetes care team.

Conclusion

Saliva testing offers an appealing possibility for making gestational diabetes screening more comfortable and accessible.

The latest research identifies promising signals involving salivary glucose, oxidative stress, metabolic proteins, and oral bacteria. However, inconsistent results and limited validation remain major barriers.

Although research on salivary biomarkers may help improve future gestational diabetes screening, current evidence does not support replacing the glucose challenge test or OGTT.

Established blood-based screening remains essential for identifying gestational diabetes and supporting appropriate prenatal care.

Frequently Asked Questions

Can a saliva test diagnose gestational diabetes?

No. Saliva-based tests remain investigational and have not demonstrated sufficient accuracy or validation to replace established blood glucose testing during pregnancy.

Which salivary biomarkers appear most promising?

Salivary glucose, malondialdehyde, and selected adipokines have shown encouraging findings. Researchers are also studying inflammatory markers and oral microbiome patterns.

Why do researchers want alternatives to the glucose drink?

Noninvasive methods could reduce discomfort, avoid needles, and make repeated testing easier. However, alternatives must first demonstrate reliable diagnostic performance.

When should pregnant patients undergo gestational diabetes screening?

Routine screening generally occurs between 24 and 28 weeks of pregnancy. Earlier testing may be appropriate for individuals with specific risk factors or suspected preexisting diabetes.

What research is needed before saliva testing becomes routine?

Larger prospective studies must establish consistent collection methods, validate diagnostic accuracy in independent populations, and evaluate whether testing improves patient outcomes.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.